ann out re immunoxel, page-43

With respect, if you serious it's way past time you saved these same old questions, but got them right, for the shareholder's meeting.

These factors have been posted on so many times in the past they have grown mould.

We are all aware that there were projected sales figures that were likely not reached for varying reasons, amoungst which of course was the halicon deal which did not got ahead due to diagreement in the terms of the potential terms and conditions wanted in the takeover contract, so it's only logical that you need to remove halicon's then substantial montly revenue from those statements.

Then there's hold ups in obtaining authorities to produce, unable to raise sufficient revenue to rev up and supply all products for sales etc., and the changing costs involved in getting the factory fully tested and approved, on going costs obtaining further patents multiple products, multiple countries, health product production, establishment and raiing of factory and pharmacy sales staff, wages, costs and overheads that no doubt blew out, as the various areas started to grow. Most of those statements were always only projections based on circumstances and some sales figures to hand at that time. They were never facts and did not take any account of actual costs, nor any other changing cicumstances.

Not defending, simple logic, and given neither you nor anyone else on this forum actually knows, I suggest you save a knowledgable well presented question about this for a shareholders meeting, and stop your negative speculation, because it without any authoritive knowledge, represents about the same thing you are complaining of and add nothing to assist anyone in their non-emotional dwecision making. Bring something new to the party by all means.